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Background aims. Ex vivo expansion of natural killer (NK) cells is a strategy to produce large numbers of these effector cells
for immunotherapy. However, the transfer of bench-top expansion protocols to clinically applicable methods is challenging
for NK cellebased therapy because of regulatory aspects and scale-up issues. Therefore, we developed an automated, large-
scale NK cell expansion process.Methods. Enriched NK cells were expanded with interleukin-2 and irradiated clinical-grade
Epstein-Barr virusetransformed lymphoblastoid feeder cells with the use of an automated system in comparison to manual
expansion, and the cells were investigated for their functionality, phenotype and gene expression. Results. Automated
expansion resulted in a mean 850-fold expansion of NK cells by day 14, yielding 1.3 (0.9)  109 activated NK cells.
Automatically and manually produced NK cells were comparable in target cell lysis, degranulation and production of
interferon-g and tumor necrosis factor-a and had similar high levels of antibody-dependent cellular cytotoxicity against
rituximab-treated leukemic cells. NK cells after automated or manual expansion showed similar gene expression and marker
proﬁles. However, expanded NK cells differed signiﬁcantly from primary NK cells including upregulation of the functional
relevant molecules TRAIL and FasL and NK celleactivating receptors NKp30, NKG2D and DNAM-1. Neither auto-
matically nor manually expanded NK cells showed reduced telomere length indicative of a conserved proliferative potential.
Conclusions.We established an automated method to expand high numbers of clinical-grade NK cells with properties similar
to their manually produced counterparts. This automated process represents a highly efﬁcient tool to standardize NK cell
processing for therapeutic applications.
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Since the discovery and description of natural killer
(NK) cells in 1975, because of their ability to
recognize and lyse tumor cells [1], it became more
and more clear how NK cells are regulated and
recognize their targets and that they play a role in
immune surveillance of cancer [2]. Parallel to the
proceeding understanding of NK cell biology, they
were evaluated in clinical settings [3]. Thus far, the
transfer of allogeneic NK cells in addition to stan-
dard hematopoietic stem cell transplantation in the
treatment of acute myeloid leukemia has proven its
feasibility and safety [4]. Furthermore, chemo-
therapy combined with NK cell infusions has been
tested for cancer treatment and seems promising
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patients that reported long-term survival, with all
children remaining in remission in a 2- to 4.2-year
follow-up [10].
Despite notable progress and development of
different strategies to optimize the therapeutic value
of NK cells [11], NK cellebased immunotherapy in
general had to deal with several challenges, which,
until now, limited its efﬁcacy. One major hurdle is to
apply sufﬁcient numbers of activated NK cells [12].
An option to increase the number and function of
donor-derived NK cells is to expand and activate the
cells ex vivo before transfer to the patient. Therefore,
NK cell expansion protocols are required that not
only efﬁciently induce NK cell proliferation and1429, Germany. E-mail: markusgr@miltenyibiotec.de or Volker Huppert,
tenyibiotec.de
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622 M. Granzin et al.activate NK cell function but also fulﬁll regulatory
requirements for safety. Furthermore, compounds
used during NK cell expansion must not be harmful
to the patient. Different protocols have recently been
established that claim to meet these requirements
and allow the production of NK cells of clinical-
grade quality [13e16].
However, the next challenge is the transfer of
these protocols to clinical scale in a manageable,
Good Manufacturing Practice (GMP)-compliant
way, and cultivation in closed systems such as cell
culture bags and G-Rex containers have demon-
strated their applicability in this context [17e20].
However, a multitude of necessary hands-on steps
complicate the routine use of these scaled-up manual
approaches as a standard therapy. In contrast, partial
automation of the cell cultivation by use of a biore-
actor has shown improved achievability of NK cell
production in large scale [16,21,22]. Nevertheless, a
complete automation of the activation and expansion
procedure of NK cells in production scale remains
challenging. Still, fully automated systems are
needed to ensure a deﬁned, highly standardized and
operator-independent manufacturing procedure that
meets clinical requirements at its best. A novel so-
lution to this goal is Miltenyi’s recently introduced
technology to perform automated clinical-scale cell
processing by use of centrifugation, magnetic cell
separation and cell cultivation within a closed system
[23]. With this system as a platform, we have
developed and optimized an automated NK cell
expansion process. The procedure is based on an
existing expansion protocol for clinical applications
that utilizes an irradiated clinical-grade Epstein-Barr
virusetransformed lymphoblastoid cell line (EBV-
LCL) as feeder cells to trigger NK cell proliferation
and yields pure and highly activated NK cells
[13,24]. In this study, we describe the automated
expansion procedure as a novel tool for immuno-
therapy and evaluated the resulting NK cell product
on a phenotypic and transcriptomic level as well as
for function in comparison to NK cells that have
been expanded manually.Methods
Cells and cell lines
Primary NK cells were obtained from healthy donor
buffy coats (Klinikum Dortmund) or leukapheresis
products (Hannover Medical School, Hannover,
Germany, or Institut für Klinische Trans-
fusionsmedizin und Immungenetik Ulm Gemein-
nützige GmbH, Ulm, Germany). The EBV-LCL
(SMI-EBV-LCL) line was provided by Dr Richard
W. Childs (National Heart, Lung and BloodInstitute, National Institutes of Health, Bethesda,
MD, USA). Human T-cell leukemia cell line 1301
was obtained from Sigma-Aldrich, and K562, Raji
and Daudi cell lines were purchased from German
Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany). All cell lines
were maintained in Roswell Park Memorial Institute
(RPMI) 1640 (Biowest) supplemented with 10%
fetal bovine serum (Biochrom) and 2 mmol/L L-
glutamine (PAA).Antibodies and ﬂow cytometric analysis
Rituximab was from Roche. All other antibodies
were obtained from Miltenyi: CD56 (REAﬁnity
antibody [REA]196) was conjugated with allophy-
cocyanin (APC)-Vio770. CD3 (BW264/56) was
conjugated with VioBlue. CD45 (5B1) was conju-
gated with VioGreen. Interferon (IFN)-g
(LT27:295), CD57 (TB03), CD159a (REA110),
CD244 (REA112), NKp80 (4A4.D10) and CD158e
(DX9) were conjugated with ﬂuorescein isothiocya-
nate (FITC). Tumor necrosis factor (TNF)-a (cA2),
CD25 (4E3), CD62L (145/15), CD159c (REA205),
CD178 (NOK-1), CD336 (2.29) and CD158b
(DX27) were conjugated with phycoerythrin. CD16
(VEP13), CD94 (REA113), CD226 (DX11),
CD253 (RIK-2.1), CD314 (BAT221), CX3CR1
(2A9-1), CD158a (REA284) and CD107a (H4A3)
were conjugated with APC. NK cells were stained as
indicated according to the product manual and
analyzed by use of the MACSQuant Analyzer X and
MACSQuantify 2.5 software. Dead cells were
excluded from the analysis by means of propidium
iodide staining. Mouse immunoglobulin (Ig)G1,
IgG2a, IgG2b, IgM or REAs conjugated with the
respective dyes were used as isotype controls.NK cell separation
For NK cell isolation from buffy coats, peripheral
blood mononuclear cell (PBMC) preparation was
performed by means of standard density-gradient
centrifugation with the use of Pancoll (PAN-Biotec).
NK cells were enriched from PBMCs by means
of CD3 depletion with the use of human CD3
MicroBeads (Miltenyi) followed by CD56 enrich-
ment with the use of use of human CD56
MicroBeads (Miltenyi), according to the user
manual. For leukapheresis products, the CliniMACS
Prodigy instrument and TS310 were used for auto-
mated T-cell receptor (TCR)-a/b-CD19 depletion
according to the application sheet. Further auto-
mated CD56 enrichment with the use of the instru-
ment was achieved by means of Program Enrichment
1, CliniMACS CD56 Reagent and tubing set TS100.
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Isolated NK cells were cultivated in TexMACS GMP
Medium (Miltenyi) supplemented with 5% human
serum type AB (Life Technologies) and 500 U/mL of
Proleukin S (Novartis), either together with 100
Gyeirradiated EBV-LCL at a ratio of 1:20 and a
starting concentration of 5.25  105 total cells/mL or
without feeder cells with a seeding density of 5 105
cells/mL. NK cell density was checked at days 7, 9, 12
and14bymeans of staining and counting viableCD3e/
CD56þ cells with the use of theMACSQuant Analyzer
X, andmediumwas replenished.Manual expansion in
T75 ﬂasks was started with 15 mL, and cells were
diluted to 5 to 8  105 NK cells/mL at the previously
mentioned time points. Automated expansion was
performed by means of the CliniMACS Prodigy in-
strument with the use of tubing set TS730, and pro-
grams that were generated with a ﬂexible programming
suite provided with the instrument. In short, a clinical
bag containing the starting cell material was connected
to the tubing set through sterile welding, and the cells
were transferred automatically to the CentriCult Unit
of the instrument. A cultivation program for tempera-
ture control and repeated input of CO2maintained the
cultivation conditions comparable to manual cultiva-
tion by means of an incubator at 37C and 5% CO2.
The cultivation was initiated with 70 mL, and the vol-
ume was increased to 140 mL at day 7 and 280 mL at
day9bypumping in freshmediumfroma reservoir bag.
Medium (210 mL) was exchanged at day 12 while the
cultivated cells were retained in the CentriCult Unit by
centrifugation.Until day 7, the cells were cultivated in a
static culture, and, after day 7, short centrifugation in-
tervals of 1 to 2 seconds were used every 30 to 60 sec-
onds to gently mix the cells, allowing highecell density
cell culture. Transfer of small volumes of the cell sus-
pension to a sterile samplepouchwas used for sampling
during the process.Cytokine production and degranulation
Cytokine production and degranulation were
analyzed by means of ﬂow cytometry. NK cells (2 
104) per well were seeded in 96-well round-bottom
plates alone, as a control, or together with 1  104
K562 cells and cultivated for 4 h in RPMI1640
supplemented with Monensin (eBioscience) and
CD107a-APC (Miltenyi) according to the user
manuals. After labeling with Fixable Aqua Dead
Stain (Life Technologies) to exclude dead cells
during the analysis, the cells were ﬁxed, per-
meabilized and stained for IFN-g, TNF-a and CD56
(Inside Stain Kit, Miltenyi). The latter marker was
used to discriminate NK cells from co-cultivated
K562 target cells.Killing assay and antibody-dependent cellular cytotoxicity
Target cell killing of K562, Raji and Daudi cell lines
was analyzed by means of a ﬂow cytometryebased
assay. Target cells were labeled with CellTrace Vi-
olet (Life Technologies) according to the user
manual. Labeled target cells (1  104) per well were
seeded in 96-well round-bottom plates and culti-
vated alone, as a control, or with NK cells at
different NK-to-target ratios as indicated. To
analyze antibody-dependent cytotoxicity, 1 mg/mL
of rituximab was added directly to the co-culture
of NK cells and target cells. After 4 h of incuba-
tion, plates were stored at 4C for 0.5 to 2 h
before the viable CellTrace Violetepositive target
cells were quantiﬁed by use of the MACSQuant
Analyzer X. The difference between the number
of viable target cells in samples with NK cells
and samples without NK cells was deﬁned as killed
target cells.Telomere length analysis
Telomere length was measured by means of ﬂow
cytometry with the use of a commercial Telomere
PNA Kit/FITC (Dako) according to the user
manual. Detection of the samples labeled with
ﬂuorescein-conjugated peptide nucleic acid was
done with the use of the MACSQuant Analyzer X.
As recommended, the cell line 1301 was used as
internal control and relative telomere length (RTL)
was calculated as follows:
RTL ¼ (mean FL1 sample cells with probemean
FL1 sample cells without probe)  2  100/(mean
FL1 control cells with probemean FL1 control cells
without probe).Gene expression
For total RNA isolation, 1  106 unexpanded and
expanded NK cells per sample were lysed in RA1
buffer (Machery-Nagel) and stored at e20C. To
ensure high purity of the starting material, only CD3-
depleted and CD56-enriched NK cells were
considered for micro-array analysis. Human total
RNA was isolated with the use of the NucleoSpin
RNA kit (Macherey-Nagel). RNA quality and
integrity were determined with the use of the Agilent
RNA 6000 Nano Kit on the Agilent 2100 Bio-
analyzer (Agilent Technologies), and RNA integrity
numbers were between 8.1 and 10. According to
published data, RNA integrity number >6 is of suf-
ﬁcient quality for gene expression proﬁling experi-
ments [25]. RNA was quantiﬁed by measurement of
A260 nm on the ND-1000 Spectrophotometer
(NanoDrop Technologies).
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Total RNA from unexpanded and expanded NK cell
samples (100 ng each) was used for the ampliﬁcation
and labeling step with the use of the Agilent Low
Input Quick Amp Labeling Kit (Agilent Technolo-
gies). Yields of complementary RNA measured with
the ND-1000 Spectrophotometer (NanoDrop
Technologies) were in all cases >5 mg, and dye
incorporation rates were in all cases >15fmol/ng.Hybridization of agilent whole human genome
oligoemicro-arrays
Hybridization was performed according to the Agi-
lent 60-mer oligoemicro-array processing protocol
with the use of the Agilent Gene Expression Hy-
bridization Kit (Agilent Technologies). Brieﬂy, 600
ng of Cy3-labeled fragmented complementary RNA
in hybridization buffer was hybridized overnight (17
h, 65C) to Agilent SurePrint G3 Human Gene
Expression Microarrays 8  60K v2 with the use of
Agilent’s recommended hybridization chamber and
oven. Fluorescence signals of the hybridized Agilent
Microarrays were detected with the use of Agilent’s
Microarray Scanner System (G2505C, Agilent
Technologies). The Agilent Feature Extraction
Software (FES 10.7.3.1) was used to read out and
process the micro-array image ﬁles.Pre-processing of micro-array data
Raw intensity data were extracted from Feature
Extraction output ﬁles for Agilent Whole Human
Genome Oligo Microarrays 8X60K v2 (Agilent
Technologies, Inc) with the use of Rosetta Resolver
software (Rosetta, Inpharmatics, LLC). All subse-
quent calculations were performed with the use of R/
Bioconductor and software packages therein [26,27].
Background-corrected intensity values were
normalized between arrays by means of quantile
normalization [28]. Reliable signal intensities were
considered at P  0.01, according to the Rosetta
error model [29]. Log2-transformed normalized in-
tensity values were used for subsequent statistical
analysis.
The data set has been uploaded to the NCBI
GEO public database: record No. GSE62654.Statistics and data analysis
Apart from micro-array data analysis, statistical
comparisons were performed with the use of un-
paired or paired Student’s t-test, as indicated. In the
micro-array data sets, signiﬁcant expressiondifferences were determined per reporter between
the following sample groups: freshly isolated NK
cells (day 0) and NK cells expanded for 14 days by
the automated system CliniMACS Prodigy (P);
manually with EBV-LCL feeder cells in T75 ﬂasks
(T) and manually without feeder cells only with the
use of IL-2econtaining media (I). The analysis of
variance test with repeated-measurements design was
applied by ﬁtting a linear mixed-effects model
(random effect: individual donors) on the normalized
log2 intensity data. Correction for multiple testing
occurred by use of the method of Benjamini &
Hochberg (B-H). Further pairwise group compari-
sons were performed by means of Tukey’s honestly
signiﬁcant differences post hoc test. The following
selection criteria were applied: adjusted analysis of
variance P values 0.05, Tukey P values 0.05 and
median fold changes 2 or e2. Reporters with a
detection P value (ﬂag) >0.01 for >3 of 6 samples
per sample group were excluded because of insufﬁ-
cient signal reliability. The expression proﬁles of all
reporters with differential gene expression in at least
one of the pairwise comparisons was hierarchically
clustered (Euclidean distance, complete linkage) and
displayed in heat map images centered to the median
value per reporter (TM4 suite, MeV_4_8_1) [30].
Calculations were performed with the use of Excel
(Microsoft Ofﬁce Inc) or R/bioconductor [R version
3.1.1 (2014e07e10)]. Because some of the reporters
covered on the micro-array platform represent long
non-coding RNAs or map to alternative transcripts
of the same gene, functional grouping analysis was
performed on the gene level with the use of QIA-
GEN’s Ingenuity Pathway Analysis annotation tools
(IPA, QIAGEN Redwood City, www.qiagen.com/
ingenuity). Signiﬁcantly enriched functional groups
were identiﬁed by use of default settings and a B-H
multiple testing P-value cutoff of 0.025.Results
The production of therapeutic effector cells in a
standardized, GMP-compliant and efﬁcient way is
challenging for several clinical applications. To
minimize the requirement for hands-on technician
time and the possibility of contamination, we devel-
oped a fully automated cell cultivation process with
the use of the CliniMACS Prodigy system and
applied it to an NK cell expansion protocol that
makes use of IL-2 and EBV-LCL feeder cells to
induce NK cell activation and proliferation. The
automation covered all cultivation steps that were
needed within 14 days, including medium change,
gentle cell mixing at high cell densities and sampling
for analysis during the expansion process.
Figure 1. Expansion kinetics and effector functions of differentially expanded NK cells. (A) Automated EBV-LCLebased expansion of NK
cells (circles) in comparison to manual NK cell expansion in T ﬂasks with (squares) or without (triangles) EBV-LCL. NK cell numbers
displayed for manual expansion are theoretical and were calculated by the NK cell fold expansion obtained in T ﬂasks multiplied by the same
starting NK cell number as in the automated approach. (B) Differentially expanded NK cells were tested for their reactivity by staining for
CD107a, IFN-g and TNF-a before (white bars) and after (gray bars) stimulation with K562 target cells. NK cells from 10 (A) or six (B)
donors were analyzed; displayed are mean values and P values for paired Student’s t-test, with P < 0.05 considered signiﬁcant.
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comparable NK cell fold expansion
Puriﬁed NK cells from buffy coat samples of 10
donors were either cultivated manually in T-75 ﬂasks
or by use of the automated system resulting in
comparable increase in NK cell numbers over time
(Figure 1A). Automated or manual EBV-LCL feeder
cell lineebased expansion for 2 weeks led to 850 
509-fold or 1344  1135-fold fold increases in NK
cell numbers, respectively, with high variability be-
tween different donors. To further investigate the
effect and necessity to use the feeder cell line, we also
cultivated NK cells manually in T-75 ﬂasks without
EBV-LCL, representing a long-term expansion with
IL-2econtaining media alone, which has been used
in clinical trials. Without EBV-LCL, only 14  13-
fold expansion was achieved, demonstrating the
limitation of this approach and the strong
proliferation-inducing effect of the LCL cell line on
NK cells. On average, starting with only 1.5  106
NK cells, a number typically obtained from 20 mL of
whole blood, a substantial number (mean, 1.3  109)
of NK cells could be produced within 14 days by a
single run of the automated process. Both the auto-
mated and manual expansion resulted in a highly
pure NK cell product (>99% CD3e/CD56þ), and
no T or B cells could be detected.Automatically and manually produced NK cells have
similar functionality
The effector functions of the differentially expanded
NK cells on stimulation with K562 target cells
revealed no differences in the production of the pro-
inﬂammatory cytokines IFN-g and TNF-a and
similar levels of degranulation as an indicator of NK
cell cytotoxic function (Figure 1B). We further
evaluated NK cell cytotoxicity against the human
leukemic cell lines K562, Raji and Daudi
(Figure 2A). NK cells obtained by means of the
automated or the manual approach showed compa-
rable cytotoxicity against all three target cell lines in
a dose-dependent manner, although signiﬁcant dif-
ferences in the cytotoxic intensity were observed
between different donors. The level of killing tended
to be higher compared with NK cells that had been
expanded with IL-2 only and without EBV-LCL,
but this trend only achieved statistical signiﬁcance
at a 10:1 effector-to-target ratio against K562 cells.
Next, we tested whether the killing of target cells
could be enhanced by a monoclonal antibody
because NK cells are able to induce antibody-
dependent cellular cytotoxicity through the Fc re-
ceptor CD16. It is known that NK cell activation
induces CD16 downregulation [31], and we
observed lower levels of CD16 on the surface of the
Figure 2. Natural and antibody-dependent cytotoxicity of differentially expanded NK cells. (A) NK cells were expanded for 14 days by
means of the automated process (black bars) in comparison to manual NK cell expansion in with (white bars) or without (gray bars) EBV-
LCL and analyzed for cytotoxicity against K562, Raji and Daudi cell lines at different effector-to-target (E:T) ratios. (B) Cytotoxicity against
CD20-positive Raji or Daudi cells that were untreated (circles) or treated (squares) with 1 mg/mL rituximab for 4 h during the assay. P values
indicated are for paired Student’s t-test, with P < 0.05 considered signiﬁcant. Six or seven donors were analyzed; displayed are mean values,
minimum to maximum (whiskers in A) and standard deviation. (C) Representative CD16 expression on NK cells from one donor is shown.
Comparison of primary NK cells (red curve) and NK cells after 14 days of automated (black curve) or manual (white curve) expansion in the
presence of EBV-LCL is displayed. CD16-negative PBMCs served as a control to determine the positive gate (blue curve). (D) Overview of
the CD16 staining of all seven donors used in B is depicted; displayed are mean values, minimum to maximum and standard deviation.
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freshly isolated cells (Figure 2C,D). Still, rituximab
signiﬁcantly increased the NK cellemediated killing
of CD20-positive Raji or Daudi cells for both auto-
matically and manually obtained NK cells, proving
that they had the capacity to mediate therapeutically
relevant antibody-dependent cellular cytotoxicity
(Figure 2B). Of note, rituximab had no effect on the
killing of CD20-negative K562 cells (Supplementary
Figure 1).Expanded NK cells do not show a reduction in telomere
length
Extensive expansion might reduce the proliferative
potential of NK cells for later in vivo applications,
which would result in telomere shortening. There-
fore, we investigated the telomere length before and
after expansion because the proliferative potential of
NK cells is crucial for their therapeutic effect after
transfer to the patient [6]. After 14 days of
Figure 3. NK cell surface marker expression investigated by means of ﬂow cytometry. NK cells were analyzed by means of ﬂow cytometry
for selected surface markers before (primary NK, dotted) or after automated EBV-LCLebased expansion (black bars) in comparison to
manual NK cell expansion in T ﬂasks with (white bars) or without (gray bars) EBV-LCL. Five donors were analyzed; mean values and
standard deviations are shown. Changes on expansion represented by differences between primary and automatically expanded NK cells
were analyzed by means of paired Student’s t-test; markers with P < 0.05 are written in bold letters. In addition, differences between
automatically and manually expanded NK cells after co-culture with EBV-LCL were analyzed by means of paired Student’s t-test; markers
with P < 0.05 are indicated as signiﬁcant by a star.
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length was detected, independent of the expansion
method and expansion intensity, indicating that the
proliferative potential of the NK cells was not
reduced, even after extensive ex vivo expansion
(Supplementary Figure 2).Flow cytometry proﬁles of automatically and manually
expanded NK cells are similar, whereas they differ clearly
from primary NK cells
Next, we compared the phenotype of primary and
expanded NK cells by means of ﬂow cytometry and
stained for 18 selected markers (Figure 3). As pre-
viously described [24], the pattern of many relevant
NK cell markers changed on ex vivo expansion.
Upregulation of TRAIL and FasL as well as the
activating NK cell receptors NKp30, NKp44,
NKG2D and DNAM-1 indicated an activated state
and correlated with the enhanced NK cell function
after expansion, which was in line with the results of
the preceding functional assays. Besides the strong
phenotypic difference between naive and expanded
NK cells in general, manually and automatically
processed NK cells had a comparable marker proﬁle.
However, frequencies of NK cells expressing
NKG2C, CX3CR1 and KIR2DL2/DL3 were
slightly but still statistically signiﬁcantly higher after
automated expansion compared with manually
expanded NK cells that showed slightly higher
expression of NKG2A and NKp44 (representative
dot plots in Supplementary Figure 3).Gene expression analysis reveals only minor differences
between NK cells after automated or manual NK cell
expansion
We further investigated the NK cells at the gene
expression level and performed a whole human
genome micro-array with samples from six donors.In total, 13,263 reporters corresponding to differ-
entially expressed transcripts were identiﬁed in the
comparisons among all sample groups (displayed in a
clustered heat map in Figure 4A). Of note, the most
prominent expression differences were between
freshly isolated and all other expanded NK cell
samples.
In contrast, and consistent with the ﬂow cytom-
etry analysis, gene expression after automated or
manual expansion with EBV-LCL feeder cells was
similar. Less than 2% of all differentially expressed
reporters (247 reporters) varied signiﬁcantly between
both sample groups. However, to obtain further
insight in associated functions for the small set of
differentially expressed genes, functional grouping
analysis was performed. The analysis revealed an
association of the genes with hematological system
development, cellular movement and immune cell
trafﬁcking. In particular, genes with known impor-
tance in movement of leukocytes were identiﬁed
(Supplementary Table I), including a group of genes
associated with NK cell migration (CMKLR1,
CX3CR1, S1PR5, GNLY and CXCR1). The latter
set of genes was expressed at slightly higher levels
after automated compared with manual expansion.
Nevertheless, the expression proﬁles of NK cells
after automated and manual expansion were strik-
ingly similar and in strong contrast to the many
differentially expressed genes between primary and
expanded NK cells. Changes between NK cells after
expansion with the automated system and naive NK
cells before expansion were investigated in more
detail; a list of the 100 most upregulated or down-
regulated genes is shown in Supplementary Tables II
and III. As expected for an expansion protocol,
functional grouping analysis revealed the most sig-
niﬁcant functional association of the regulated genes
(B-H P values <1.5  108) with cell cycle regula-
tion, cell death and survival, DNA replication, DNA
recombination and DNA repair, cellular growth and
Figure 4. Gene expression proﬁles of NK cells before and after expansion. Samples from six donors were used for gene expression analysis of
primary NK cells and NK cells after automated EBV-LCLebased expansion as well as NK cells after manual expansion in T ﬂasks with or
without EBV-LCL. (A) Differentially regulated reporters between the four sample groups were identiﬁed by ﬁltering for statistical relevance
and reliable signal intensities; median centered values for these reporters are shown in a heat map after hierarchical clustering analysis. Color
saturation limits range from log2 intensities of 4 (green) to þ4 (red). No changes relative to the reporter-wise median log2 intensity of all
samples is displayed in black color. (B) Filtering for NK cellerelevant genes among regulated reporters is displayed for NK cells obtained by
the automated process (black bars), manual expansion with EBV-LCL feeders (white bars) or manual expansion without EBV-LCL feeders
(gray bars) in relation to primary NK cells. Automated and EBV-LCLebased manual expansion was compared by means of Tukey’s
honestly signiﬁcant differences post hoc test; genes with Tukey P value 0.05 and median fold change 2 or 2 are indicated as signiﬁcant
(indicated by stars).
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nization. Consistent with the results of the ﬂow
cytometry analyses, many NK cell markers had a
change in their expression levels after expansion
(Figure 4B). The most prominent effects were
upregulation of TRAIL, FasL, the inhibitory recep-
tor TIGIT and the chemokine receptors CCR2,
CCR5 and CXCR6. In addition, granzyme M was
downregulated, but other effector molecules that
play an important role in tumor killing, such as TNF-
a, perforin and granzymes A, B and K, were
upregulated.Automated NK cell expansion can be complemented by a
preceding, automated NK cell separation, enabling a fully
automated NK cell production process
Finally, we also performed initial NK cell puriﬁca-
tion steps automated by means of the CliniMACS
Prodigy system before the automated cultivation andexpansion phase to show that the complete cell
processing needed for NK cell expansion, from the
starting material to the ﬁnal cell product inclusive of
the NK cell enrichment process, can be achieved
with the use of this system. We started with TCR-a/
b-CD19 depletion, to ensure efﬁcient removal of
potentially harmful contaminating TCR-a/bþ T and
B cells, followed by CD56-positive selection in a
second step to further enrich for puriﬁed NK cells.
By use of this strategy, automated NK cell separa-
tions from leukapheresis products of three donors
were performed and 4,1e4,4 and 2,7e3,1 log
depletion of TCR-a/b and B cells was achieved. After
subsequent CD56 enrichment, no TCR-a/b and B
cells were detected, and NK cells with a purity of
71% to 92% could be obtained while remaining non-
NK cells were mainly CD14þ monocytes (12.4% 
8.8%) and TCR-gd CD3þCD56þ NK-like T cells
(5.3%  4.7%). Automated expansion of automati-
cally separated NK cells for 14 days resulted in
Automated expansion of clinical-grade NK cells for immunotherapy 629390-fold to 1185-fold expansion (Supplementary
Figure 4A), within the same range of what was ach-
ieved by manually separated NK cells before. The
functionality of the fully automatically obtained NK
cells was proven by the effective killing of K562, Raji
and Daudi cells (Supplementary Figure 4B).
In summary, we expanded substantial numbers of
activated NK cells through the use of a completely
automated system. These automatically produced
NK cells, in comparison to their manually produced
counterparts, had similar phenotypic, transcriptional
and functional proﬁles.Discussion
We successfully developed the automated cell
expansion processes by the use of an automated
system and report our results on production of acti-
vated NK cells for their use in clinical cell therapy
applications. For large-scale expansion of clinical-
grade cells, NK cell cultures normally are main-
tained for 14 to 28 days and typically require
frequent interventions such as media changes to
refresh cytokines and other growth factors as well as
to ensure that NK cells are maintained at a concen-
tration that optimizes their growth and viability [32].
We efﬁciently automated this procedure and gener-
ated high NK cell numbers that showed the same
in vitro functionality and similar phenotype and gene
expression as manually expanded NK cells. The
automation within a closed system substantially fa-
cilitates the expansion procedure by saving not only
time but also minimizing the risk of culture
contamination while introducing consistency in the
production process. In addition, the automation re-
quires ﬁnancial investment for the instrument but
enables signiﬁcantly reduced running costs for an
actively used clean-room, representing a major
expense factor for the cellular product. Therefore,
the automated process will be cost-saving in pro-
duction scale and performance of numerous pro-
cesses per year.
In line with previous ﬁndings, many NK
cellerelevant markers and apoptosis-inducing mole-
cules were upregulated on ex vivo expansion and
might contribute to an increase of the therapeutic
potential of the ex vivoegenerated NK cells [24]. In
particular, upregulation of TRAIL by expanded NK
cells can be utilized to efﬁciently treat tumors that
express TRAIL death receptors and/or are sensitized
to TRAIL by drugs such as bortezomib [33].
Although several methods for effective NK cell
expansion were developed in the past and have
proven their applicability in large-scale by use of
manual cultivation systems such as cell culture bags
or G-Rex containers [13,14,17e19], there has beenvirtually no progress in the development of a fully
automated and controlled process for clinical-scale
NK cell expansion. Sutlu et al. [17] and Lapteva
et al. [22], independent of each other, applied an
automated Wave Bioreactor system for clinical-grade
NK cell expansion from PBMCs, and Spanholtz
et al. [21] used the same system to generate clinical-
grade NK cells expanded from cord blood hemato-
poietic progenitor cells. Sutlu et al. [17] concluded
that automation of the cultivation is more practical
and generated more activated NK cells compared
with manual approaches. We conﬁrm the practica-
bility of an automated system, whereas, in our hands,
NK cells neither differed signiﬁcantly in phenotype
nor in function, whether they have been cultivated
manually or automatically, similar to observations
from Lapteva and Spanholtz et al. In comparison, the
Wave Bioreactor system requires a high cell number
to initiate the culture, which inevitably implicates a
manual pre-cultivation until enough cells are gener-
ated to start the automated process. In the system
presented here, low starting cell numbers were not a
limitation because the automation covered the whole
cultivation phase including an early static cultivation
phase with very low cell numbers, with 106 NK cells
being sufﬁcient to initiate the current process.
In addition and in contrast to other expansion
approaches, we show that the entire cell cultivation
phase, including the preceding cell separation steps,
can be fully automated by a single instrument,
enabling complete cell processing from the starting
material to the ﬁnal “ready-to-use” cell product. To
start the NK cell expansion with enriched NK cells is
beneﬁcial because it results in high-purity expanded
NK cells without contaminating T cells in the ﬁnal
cell product [13,34].
On average, we could generate 1.3  109 acti-
vated NK cells with one instrument within 2 weeks,
enough to treat a typical 70- to 100-kg patient with 1
to 2  107 NK cells/kg. This would fall within the
range of NK cells typically used in investigational
trials of adoptive NK cell immunotherapy [3].
Nevertheless, the optimal dose for NK cell injections
has not yet been determined, and, because no dose
dependent side effects have been observed, NK cell
injections of 108 to 109/kg are imaginable in future
[32]. Whereas bioreactor systems provide a volume
of up to 3 L for cultivation and can yield 2  109 NK
cells derived from umbilical cord blood hematopoi-
etic stem cells [16] or 9.8  109 NK cells from
expansion of PBMCs [21,22], our current system is
equipped with a medium scale culture volume of
only 300 mL, which allowed a maximum NK cell
number of 2.7  109. Thus, if mega-doses of NK
cells are needed, several process runs or multiple
devices might be necessary for one application.
630 M. Granzin et al.Integration of a bioreactor in the system may be
another option to enable fully automated processes
that can include cell separation followed by an initial
expansion and a late cultivation phase at higher
culture volumes. With the current instrumentation, it
is already possible to perform a continuously running
process that maintains the NK cells in the expansion
phase with repeated harvesting of cells whenever the
maximum cell density is reached.
On the other hand, the number of NK cells that is
required for the transfer to the a patient may be
lower, if better in vivo persistence and expansion of
the transferred cells could be achieved through post-
infusion maneuvers such as cytokine administration.
Clinical trials showed that it is possible to induce
in vivoNK cell expansion in humans by means of IL-
2 injection or endogenous production of IL-15 that
can be stimulated by distinct immune suppressive
regimen [7,35]. Importantly, NK cells produced
with the use of the automated method showed no
noticeable telomere length shortening after expan-
sion, indicating that the cells do not become senes-
cent, and the regular proliferative potential is
conserved potentially, allowing ex vivoeexpanded
NK cells to further expand in vivo. However, this
must be proven in a suitable animal model or clinical
application.
Another aspect to consider is that NK cells are
heterogeneous in phenotype and function, with only
a fraction of NK cell subsets driving their major
cytotoxic effects [36,37]. As a consequence, effective
NK cellebased immunotherapy may not necessarily
require the transfer of a high number of bulk NK
cells but the transfer of sufﬁcient cells of therapeu-
tically relevant NK cell subsets. Detailed character-
ization of these subsets is pending, but, because the
automated expansion system inimitably combines
the feature of cell separation and the possibility to use
a very low starting NK cell number for expansion, it
would be possible to isolate only a rare, therapeuti-
cally relevant NK cell subset and expand these cells
to clinically needed numbers within a single process,
representing a promising future strategy.
In the present study, we automated our system
through the use of TCR-a/b-CD19 depletion fol-
lowed by CD56 enrichment as a novel strategy to
enrich for bulk NK cells in clinical scale from leu-
kapheresis products because TCR-a/b depletion has
been shown to be superior over conventional CD3
depletion as the result of a more efﬁcient removal of
TCR-a/b T cells, which are responsible for graft-
versus-host disease [38]. We achieved a highly efﬁ-
cient depletion of TCR-a/b cells and obtained NK
cells that had the same potential to proliferate and
showed the same functionality after expansion as NK
cells, which were obtained by CD3 depletion andCD56 enrichment. The latter method has been used
as a standard strategy for NK cell separation in
clinical scale in investigational therapeutic settings
[20,39,40].
In view of the need to develop standardized
methods to expand NK cells that are being investi-
gated for their therapeutic potential in the clinic, this
automated process enables easy up-scaling for
centralized manufacturing of the therapeutic cell
product. Furthermore, the closed system allows
scale-out strategies and decentralized cell processing
directly at the location of use, avoiding the need for
cell shipping, which often represents a logistic chal-
lenge, and, if done incorrectly, can compromise the
product quality [22].
In conclusion, the automation of the entire NK
cell expansion process presented in the present
report represents a novel procedure with the use of a
single instrument that allows for the efﬁcient pro-
duction of clinical-grade NK effector cells. Because
all processing steps are done automated in a closed
system, this provides the highest standards for GMP
conformity. Most importantly, this automated pro-
cess represents a highly efﬁcient and much-needed
tool to standardize NK cell processing for thera-
peutic applications.Acknowledgments
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